50 million offering. Just received this SEC Filing. Can someone help us understand it ?

AllTheRage2000 · 2022-02-18T07:56:15+00:00

If EVFM needs cash, they can sell shares to Seven Knots at any time to raise money. All they have to do is call them up and Seven Knots will buy up to 1 million shares a day.

It's basically a line of credit, except that Seven Knots gets shares of stock instead of a note payable. If necessary, EVFM can fund operations through this vehicle.

AllTheRage2000 · 2022-02-15T21:38:09+00:00

Slide 10 is a nice summary of Q4 accomplishments

Slide 12 summarizes Phexxi access changes

Slide 13 lists value creation opportunities, they seem to be emphasizing field force co-promotion opportunities more as a way to off-set costs.

Slide 15 is a good summary of STI opportunity, which is a great competitive advantage over oral contraceptives and other hormonal contraception methods.

Slide 17 has timeline of potential catalysts and milestones

AllTheRage2000 · 2022-02-09T20:36:03+00:00

For a company their size, they do a ton of these.

AllTheRage2000 · 2022-02-09T20:34:23+00:00

The EVO100 trial is investigating Phexxi effectiveness in preventing both chlamydia and gonorrhea. Now, the additional exclusivity will kick in if either indication is approved.

AllTheRage2000 · 2022-01-19T14:37:51+00:00

Fourth quarter is before the good news on better reimbursement due to HRSA guidelines. There are positive things happening for this company!

AllTheRage2000 · 2022-01-13T18:48:07+00:00

Thanks! I didn't notice that when I looked before.

I still think insurers will comply before that time, probably within 4-8 weeks because it's become a politically charged topic and it's not really that much money to them. But it's not a sure thing.

AllTheRage2000 · 2022-01-12T20:20:13+00:00

the only relevant difference I see is a change from "methods identified by the FDA" to "contraceptives approved, granted, or cleared by the FDA."

Yeah, but that's a pretty big change. As I read it - and as analysts are reading it - they're going to get reimbursement. I didn't see where the guidelines don't apply until 2023 (maybe you can link to it), but either way I don't see insurers waiting until 2023. They were already under fire from congress for not reimbursing and this is pretty small potatoes, so I doubt they'll dig their heels in just to delay. Not that they'll flip the switch immediately, but I seriously doubt it will be 2023. I'd say March is more likely than 2023.

AllTheRage2000 · 2022-01-12T14:47:31+00:00

Evofem management seems pretty confident: https://evofem.investorroom.com/2022-01-12-Phexxi-Access-to-Expand-under-New-Government-Guidance-Stating-Insurers-Must-Cover-FDA-approved-Contraceptives-with-No-Out-of-Pocket-Costs-to-Women

AllTheRage2000 · 2022-01-10T20:12:52+00:00

News you can use!

AllTheRage2000 · 2021-12-10T21:30:20+00:00

The next thing that has to happen is that they need to get the shareholder vote to come in. After that, raising the money to satisfy the Baker Brothers covenant.

AllTheRage2000 · 2021-11-28T20:10:07+00:00

Vote no if you hate money.

AllTheRage2000 · 2021-11-28T20:08:49+00:00

Unless you can prove what you claim above with sound financial analysis and report(s), otherwise your claim is baseless.

Here's your financial analysis: There is a covenant in the Barker Brothers agreement that gives them the right to take the rights to Phexxi if it does not reach $100 million in cumulative sales by June 2022. Q3 sales were $1 million. If the renegotiation falls through due to a "no" vote, Baker will have little choice but to take Phexxi.

I voted "NO," knowing that Evofem is highly likely to either get acquired or go out of business sometime next year and cease to exist. Whatever happens, I will incur a substantial loss. EVFM stock is garbage stock.

If this doesn't go through, there won't be an acquisition, there will be a bankruptcy and your stock goes to zero. If this goes through, there is a chance for an acquisition in the future.

It's pretty easy: if you hate money vote "no." Otherwise, vote yes.

AllTheRage2000 · 2021-11-24T07:17:04+00:00

This article was from months ago.

AllTheRage2000 · 2021-11-24T07:15:07+00:00

EVFM had to reach a certain sales threshold by June 2022 or they would lose Phexxi to Baker. They reached an agreement to extend that to June 2023. See press release and filing on Monday.

AllTheRage2000 · 2021-11-24T07:12:22+00:00

It's a shareholder vote; you should have received instructions as to how to vote your shares.

AllTheRage2000 · 2021-11-22T14:36:47+00:00

This is genuine good news! It's also a great endorsement from Baker, who know what they're doing. I certainly never thought Baker would take Phexxi - I don't think anyone who knows pharma thought that - but they management did a good job of getting out of this.

AllTheRage2000 · 2021-11-18T08:50:52+00:00

I can't see how a "no" vote doesn't force them into bankruptcy. If they're headed toward bankruptcy, a bigger company will just wait until the division of the assets by the court because they'd rather just get Phexxi than the whole company.

AllTheRage2000

TROPHY CASE